From tumor prevention to therapy: Empowering p53 to fight back

Drug Resistance Updates

Volumn 15, Issue 5-6, 2012, Pages 258-267

  Frezza, Christian ^a   Martins, Carla P ^a  

^a HUTCHISON MRC RESEARCH CENTRE   (United Kingdom)

Author keywords

Cancer therapy; Metabolism; p53; Tumor suppression

Indexed keywords

6 PHOSPHOFRUCTOKINASE; DEOXYRIBONUCLEOTIDE; DOXORUBICIN; GEMCITABINE; GENDICINE; HEXOKINASE; MESSENGER RNA; NUTLIN 3; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53; PUMA PROTEIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; RIBONUCLEOTIDE REDUCTASE; UBIQUITIN PROTEIN LIGASE E3;

APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER CELL; CANCER INHIBITION; CANCER PREVENTION; CANCER RADIOTHERAPY; CARCINOGENESIS; CELL AGING; CELL CYCLE; CELL CYCLE ARREST; CELL STRESS; CLINICAL TRIAL (TOPIC); DNA DAMAGE; DNA STRAND BREAKAGE; GENE MUTATION; GENE OVEREXPRESSION; GENOTOXICITY; HUMAN; LUNG TUMOR; LYMPHOMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SARCOMA; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE; XENOGRAFT;

ANIMALS; HUMANS; MICE; MUTATION; NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84870524947     PISSN: 13687646     EISSN: 15322084     Source Type: Journal    
DOI: 10.1016/j.drup.2012.10.001     Document Type: Article

References (105)

1. M. Adorno, M. Cordenonsi, M. Montagner, S. Dupont, C. Wong, B. Hann, A. Solari, S. Bobisse, M.B. Rondina, and V. Guzzardo A mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis Cell 137 2009 87 98
2. J.F. Armstrong, M.H. Kaufman, D.J. Harrison, and A.R. Clarke High-frequency developmental abnormalities in p53-deficient mice Current Biology 5 1995 931 936
3. S.J. Baker, E.R. Fearon, J.M. Nigro, S.R. Hamilton, A.C. Preisinger, J.M. Jessup, P. vanTuinen, D.H. Ledbetter, D.F. Barker, and Y. Nakamura Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas Science 244 1989 217 221
4. Y. Barak, T. Juven, R. Haffner, and M. Oren mdm2 expression is induced by wild type p53 activity EMBO Journal 12 1993 461 468
5. K. Bensaad, E.C. Cheung, and K.H. Vousden Modulation of intracellular ROS levels by TIGAR controls autophagy EMBO Journal 28 2009 3015 3026
6. K. Bensaad, A. Tsuruta, M.A. Selak, M.N. Vidal, K. Nakano, R. Bartrons, E. Gottlieb, and K.H. Vousden TIGAR, a p53-inducible regulator of glycolysis and apoptosis Cell 126 2006 107 120
7. A. Bourdon, L. Minai, V. Serre, J.P. Jais, E. Sarzi, S. Aubert, D. Chretien, P. de Lonlay, V. Paquis-Flucklinger, and H. Arakawa Mutation of RRM2B, encoding p53-controlled ribonucleotide reductase (p53R2), causes severe mitochondrial DNA depletion Nature Genetics 39 2007 776 780
8. C.A. Brady, D. Jiang, S.S. Mello, T.M. Johnson, L.A. Jarvis, M.M. Kozak, D. Kenzelmann Broz, S. Basak, E.J. Park, and M.E. McLaughlin Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression Cell 145 2011 571 583
9. M.H. Brodsky, W. Nordstrom, G. Tsang, E. Kwan, G.M. Rubin, and J.M. Abrams Drosophila p53 binds a damage response element at the reaper locus Cell 101 2000 103 113
10. R. Brosh, and V. Rotter When mutants gain new powers: news from the mutant p53 field Nature Reviews Cancer 9 2009 701 713
11. V.J. Bykov, N. Issaeva, A. Shilov, M. Hultcrantz, E. Pugacheva, P. Chumakov, J. Bergman, K.G. Wiman, and G. Selivanova Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound Nature Medicine 8 2002 282 288
12. C.F. Cheok, C.S. Verma, J. Baselga, and D.P. Lane Translating p53 into the clinic Nature Reviews Clinical Oncology 8 2011 25 37
13. M.A. Christophorou, D. Martin-Zanca, L. Soucek, E.R. Lawlor, L. Brown-Swigart, E.W. Verschuren, and G.I. Evan Temporal dissection of p53 function in vitro and in vivo Nature Genetics 37 2005 718 726
14. M.A. Christophorou, I. Ringshausen, A.J. Finch, L.B. Swigart, and G.I. Evan The pathological response to DNA damage does not contribute to p53-mediated tumour suppression Nature 443 2006 214 217
15. W.M. Claudino, P.H. Goncalves, A. di Leo, P.A. Philip, and F.H. Sarkar Metabolomics in cancer: a bench-to-bedside intersection Critical Reviews in Oncology/Hematology 84 1 2012 1 7
16. C.V. Dang MYC on the path to cancer Cell 149 2012 22 35
17. L.A. Donehower, M. Harvey, B.L. Slagle, M.J. McArthur, C.A. Montgomery Jr., J.S. Butel, and A. Bradley Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours Nature 356 1992 215 221
18. A. Efeyan, I. Garcia-Cao, D. Herranz, S. Velasco-Miguel, and M. Serrano Tumour biology: policing of oncogene activity by p53 Nature 443 2006 159
19. S. Endo, K. Yamato, S. Hirai, T. Moriwaki, K. Fukuda, H. Suzuki, M. Abei, I. Nakagawa, and I. Hyodo Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells Cancer Science 102 2011 605 613
20. D.M. Feldser, K.K. Kostova, M.M. Winslow, S.E. Taylor, C. Cashman, C.A. Whittaker, F.J. Sanchez-Rivera, R. Resnick, R. Bronson, and M.T. Hemann Stage-specific sensitivity to p53 restoration during lung cancer progression Nature 468 2010 572 575
21. Z. Feng, H. Zhang, A.J. Levine, and S. Jin The coordinate regulation of the p53 and mTOR pathways in cells Proceedings of the National Academy of Sciences of the United States of America 102 2005 8204 8209
22. C.A. Finlay, P.W. Hinds, and A.J. Levine The p53 proto-oncogene can act as a suppressor of transformation Cell 57 1989 1083 1093
23. C. Frezza, and E. Gottlieb Mitochondria in cancer: not just innocent bystanders Seminars in Cancer Biology 19 2009 4 11
24. D. Garcia, M.R. Warr, C.P. Martins, L. Brown Swigart, E. Passegue, and G.I. Evan Validation of MdmX as a therapeutic target for reactivating p53 in tumors Genes & Development 25 2011 1746 1757
25. I. Goldstein, V. Marcel, M. Olivier, M. Oren, V. Rotter, and P. Hainaut Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies Cancer Gene Therapy 18 2011 2 11
26. D.R. Green, and G. Kroemer Cytoplasmic functions of the tumour suppressor p53 Nature 458 2009 1127 1130
27. M.T. Hemann, J.T. Zilfou, Z. Zhao, D.J. Burgess, G.J. Hannon, and S.W. Lowe Suppression of tumorigenesis by the p53 target PUMA Proceedings of the National Academy of Sciences of the United States of America 101 2004 9333 9338
28. H. Hermeking MicroRNAs in the p53 network: micromanagement of tumour suppression Nature Reviews Cancer 12 2012 613 626
29. W. Hu, C. Zhang, R. Wu, Y. Sun, A. Levine, and Z. Feng Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function Proceedings of the National Academy of Sciences of the United States of America 107 2010 7455 7460
30. T. Ide, L. Brown-Endres, K. Chu, P.P. Ongusaha, T. Ohtsuka, W.S. El-Deiry, S.A. Aaronson, and S.W. Lee GAMT, a p53-inducible modulator of apoptosis, is critical for the adaptive response to nutrient stress Molecular Cell 36 2009 379 392
31. E.L. Jackson, K.P. Olive, D.A. Tuveson, R. Bronson, D. Crowley, M. Brown, and T. Jacks The differential effects of mutant p53 alleles on advanced murine lung cancer Cancer Research 65 2005 10280 10288
32. J.G. Jackson, V. Pant, Q. Li, L.L. Chang, A. Quintas-Cardama, D. Garza, O. Tavana, P. Yang, T. Manshouri, and Y. Li p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer Cancer Cell 21 2012 793 806
33. S.N. Jones, A.E. Roe, L.A. Donehower, and A. Bradley Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53 Nature 378 1995 206 208
34. M.R. Junttila, A.N. Karnezis, D. Garcia, F. Madriles, R.M. Kortlever, F. Rostker, L. Brown Swigart, D.M. Pham, Y. Seo, and G.I. Evan Selective activation of p53-mediated tumour suppression in high-grade tumours Nature 468 2010 567 571
35. M. Kaghad, H. Bonnet, A. Yang, L. Creancier, J.C. Biscan, A. Valent, A. Minty, P. Chalon, J.M. Lelias, and X. Dumont Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers Cell 90 1997 809 819
36. T. Kamijo, J.D. Weber, G. Zambetti, F. Zindy, M.F. Roussel, and C.J. Sherr Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2 Proceedings of the National Academy of Sciences of the United States of America 95 1998 8292 8297
37. T. Kamijo, F. Zindy, M.F. Roussel, D.E. Quelle, J.R. Downing, R.A. Ashmun, G. Grosveld, and C.J. Sherr Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF Cell 91 1997 649 659
38. M.B. Kastan, O. Onyekwere, D. Sidransky, B. Vogelstein, and R.W. Craig Participation of p53 protein in the cellular response to DNA damage Cancer Research 51 1991 6304 6311
39. K. Kawauchi, K. Araki, K. Tobiume, and N. Tanaka p53 regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation Nature Cell Biology 10 2008 611 618
40. C.J. Kemp, T. Wheldon, and A. Balmain p53-deficient mice are extremely susceptible to radiation-induced tumorigenesis Nature Genetics 8 1994 66 69
41. N. King, M.J. Westbrook, S.L. Young, A. Kuo, M. Abedin, J. Chapman, S. Fairclough, U. Hellsten, Y. Isogai, and I. Letunic The genome of the choanoflagellate Monosiga brevicollis and the origin of metazoans Nature 451 2008 783 788
42. P. Kleihues, B. Schauble, A. zur Hausen, J. Esteve, and H. Ohgaki Tumors associated with p53 germline mutations: a synopsis of 91 families The American Journal of Pathology 150 1997 1 13
43. H. Kondoh, M.E. Lleonart, J. Gil, J. Wang, P. Degan, G. Peters, D. Martinez, A. Carnero, and D. Beach Glycolytic enzymes can modulate cellular life span Cancer Research 65 2005 177 185
44. W.H. Koppenol, P.L. Bounds, and C.V. Dang Otto Warburg's contributions to current concepts of cancer metabolism Nature Reviews Cancer 11 2011 325 337
45. J.M. Lambert, P. Gorzov, D.B. Veprintsev, M. Soderqvist, D. Segerback, J. Bergman, A.R. Fersht, P. Hainaut, K.G. Wiman, and V.J. Bykov PRIMA-1 reactivates mutant p53 by covalent binding to the core domain Cancer Cell 15 2009 376 388
46. D.P. Lane Cancer. p53, guardian of the genome Nature 358 1992 15 16
47. G.A. Lang, T. Iwakuma, Y.A. Suh, G. Liu, V.A. Rao, J.M. Parant, Y.A. Valentin-Vega, T. Terzian, L.C. Caldwell, and L.C. Strong Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome Cell 119 2004 861 872
48. A.J. Levine, and M. Oren The first 30 years of p53: growing ever more complex Nature Reviews Cancer 9 2009 749 758
49. T. Li, N. Kon, L. Jiang, M. Tan, T. Ludwig, Y. Zhao, R. Baer, and W. Gu Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence Cell 149 2012 1269 1283
50. T. Lin, C. Chao, S. Saito, S.J. Mazur, M.E. Murphy, E. Appella, and Y. Xu p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression Nature Cell Biology 7 2005 165 171
51. Y. Liu, S.E. Elf, Y. Miyata, G. Sashida, G. Huang, S. Di Giandomenico, J.M. Lee, A. Deblasio, S. Menendez, and J. Antipin p53 regulates hematopoietic stem cell quiescence Cell Stem Cell 4 2009 37 48
52. S.W. Lowe, E. Cepero, and G. Evan Intrinsic tumour suppression Nature 432 2004 307 315
53. S.W. Lowe, and C.J. Sherr Tumor suppression by Ink4a-Arf: progress and puzzles Current Opinion in Genetics & Development 13 2003 77 83
54. W.J. Lu, J.F. Amatruda, and J.M. Abrams p53 ancestry: gazing through an evolutionary lens Nature Reviews Cancer 9 2009 758 762
55. S.Y. Lunt, and M.G. Vander Heiden Aerobic glycolysis: meeting the metabolic requirements of cell proliferation Annual Review of Cell and Developmental Biology 27 2011 441 464
56. O.D. Maddocks, and K.H. Vousden Metabolic regulation by p53 Journal of Molecular Medicine 89 2011 237 245
57. M.C. Maiuri, L. Galluzzi, E. Morselli, O. Kepp, S.A. Malik, and G. Kroemer Autophagy regulation by p53 Current Opinion in Cell Biology 22 2010 181 185
58. J.C. Marine, S. Francoz, M. Maetens, G. Wahl, F. Toledo, and G. Lozano Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4 Cell Death and Differentiation 13 2006 927 934
59. C.P. Martins, L. Brown-Swigart, and G.I. Evan Modeling the therapeutic efficacy of p53 restoration in tumors Cell 127 2006 1323 1334
60. S.P. Mathupala, C. Heese, and P.L. Pedersen Glucose catabolism in cancer cells. The type II hexokinase promoter contains functionally active response elements for the tumor suppressor p53 The Journal of Biological Chemistry 272 1997 22776 22780
61. S. Matoba, J.G. Kang, W.D. Patino, A. Wragg, M. Boehm, O. Gavrilova, P.J. Hurley, F. Bunz, and P.M. Hwang p53 regulates mitochondrial respiration Science 312 2006 1650 1653
62. K. Meletis, V. Wirta, S.M. Hede, M. Nister, J. Lundeberg, and J. Frisen p53 suppresses the self-renewal of adult neural stem cells Development 133 2006 363 369
63. L. Mendoza, E. Orozco, M.A. Rodriguez, G. Garcia-Rivera, T. Sanchez, E. Garcia, and P. Gariglio Ehp53, an Entamoeba histolytica protein, ancestor of the mammalian tumour suppressor p53 Microbiology 149 2003 885 893
64. D. Michalovitz, O. Halevy, and M. Oren Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53 Cell 62 1990 671 680
65. A.A. Mills, B. Zheng, X.J. Wang, H. Vogel, D.R. Roop, and A. Bradley p63 is a p53 homologue required for limb and epidermal morphogenesis Nature 398 1999 708 713
66. J. Momand, G.P. Zambetti, D.C. Olson, D. George, and A.J. Levine The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation Cell 69 1992 1237 1245
67. R. Montes de Oca Luna, D.S. Wagner, and G. Lozano Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53 Nature 378 1995 203 206
68. P.A. Muller, P.T. Caswell, B. Doyle, M.P. Iwanicki, E.H. Tan, S. Karim, N. Lukashchuk, D.A. Gillespie, R.L. Ludwig, and P. Gosselin Mutant p53 drives invasion by promoting integrin recycling Cell 139 2009 1327 1341
69. P.A. Muller, K.H. Vousden, and J.C. Norman p53 and its mutants in tumor cell migration and invasion The Journal of Cell Biology 192 2011 209 218
70. D.J. Murphy, M.R. Junttila, L. Pouyet, A. Karnezis, K. Shchors, D.A. Bui, L. Brown-Swigart, L. Johnson, and G.I. Evan Distinct thresholds govern Myc's biological output in vivo Cancer Cell 14 2008 447 457
71. S. Okamura, C.C. Ng, K. Koyama, Y. Takei, H. Arakawa, M. Monden, and Y. Nakamura Identification of seven genes regulated by wild-type p53 in a colon cancer cell line carrying a well-controlled wild-type p53 expression system Oncology Research 11 1999 281 285
72. J.D. Oliner, K.W. Kinzler, P.S. Meltzer, D.L. George, and B. Vogelstein Amplification of a gene encoding a p53-associated protein in human sarcomas Nature 358 1992 80 83
73. M. Ollmann, L.M. Young, C.J. Di Como, F. Karim, M. Belvin, S. Robertson, K. Whittaker, M. Demsky, W.W. Fisher, and A. Buchman Drosophila p53 is a structural and functional homolog of the tumor suppressor p53 Cell 101 2000 91 101
74. K. Onel, and C. Cordon-Cardo MDM2 and prognosis Molecular Cancer Research 2 2004 1 8
75. Z. Peng Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers Human Gene Therapy 16 2005 1016 1027
76. G. Pontarin, P. Ferraro, L. Bee, P. Reichard, and V. Bianchi Mammalian ribonucleotide reductase subunit p53R2 is required for mitochondrial DNA replication and DNA repair in quiescent cells Proceedings of the National Academy of Sciences of the United States of America 109 2012 13302 13307
77. J.E. Purvis, K.W. Karhohs, C. Mock, E. Batchelor, A. Loewer, and G. Lahav p53 dynamics control cell fate Science 336 2012 1440 1444
78. Y. Pylayeva-Gupta, E. Grabocka, and D. Bar-Sagi RAS oncogenes: weaving a tumorigenic web Nature Reviews Cancer 11 2011 761 774
79. C. Rinaldo, A. Prodosmo, F. Mancini, S. Iacovelli, A. Sacchi, F. Moretti, and S. Soddu MDM2-regulated degradation of HIPK2 prevents p53Ser46 phosphorylation and DNA damage-induced apoptosis Molecular Cell 25 2007 739 750
80. I. Ringshausen, C.C. O'Shea, A.J. Finch, L.B. Swigart, and G.I. Evan Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo Cancer Cell 10 2006 501 514
81. P. Rubin, and G.W. Casarett Clinical radiation pathology as applied to curative radiotherapy Cancer 22 1968 767 778
82. C.J. Sarkisian, B.A. Keister, D.B. Stairs, R.B. Boxer, S.E. Moody, and L.A. Chodosh Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis Nature Cell Biology 9 2007 493 505
83. C.A. Schmitt, M.E. McCurrach, E. de Stanchina, R.R. Wallace-Brodeur, and S.W. Lowe INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53 Genes and Development 13 1999 2670 2677
84. F. Schwartzenberg-Bar-Yoseph, M. Armoni, and E. Karnieli The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression Cancer Research 64 2004 2627 2633
85. P. Secchiero, R. Bosco, C. Celeghini, and G. Zauli Recent advances in the therapeutic perspectives of Nutlin-3 Current Pharmaceutical Design 17 2011 569 577
86. M.A. Smit, and D.S. Peeper Deregulating EMT and senescence: double impact by a single twist Cancer Cell 14 2008 5 7
87. S. Suzuki, T. Tanaka, M.V. Poyurovsky, H. Nagano, T. Mayama, S. Ohkubo, M. Lokshin, H. Hosokawa, T. Nakayama, and Y. Suzuki Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species Proceedings of the National Academy of Sciences of the United States of America 107 2010 7461 7466
88. H. Tanaka, H. Arakawa, T. Yamaguchi, K. Shiraishi, S. Fukuda, K. Matsui, Y. Takei, and Y. Nakamura A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage Nature 404 2000 42 49
89. D.A. Tennant, R.V. Duran, and E. Gottlieb Targeting metabolic transformation for cancer therapy Nature Reviews Cancer 10 2010 267 277
90. T. Van Maerken, L. Ferdinande, J. Taildeman, I. Lambertz, N. Yigit, L. Vercruysse, A. Rihani, M. Michaelis, J. Cinatl Jr., and C.A. Cuvelier Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53 Journal of the National Cancer Institute 101 2009 1562 1574
91. L.T. Vassilev, B.T. Vu, B. Graves, D. Carvajal, F. Podlaski, Z. Filipovic, N. Kong, U. Kammlott, C. Lukacs, and C. Klein In vivo activation of the p53 pathway by small-molecule antagonists of MDM2 Science 303 2004 844 848
92. A. Ventura, D.G. Kirsch, M.E. McLaughlin, D.A. Tuveson, J. Grimm, L. Lintault, J. Newman, E.E. Reczek, R. Weissleder, and T. Jacks Restoration of p53 function leads to tumour regression in vivo Nature 445 2007 661 665
93. B. Vogelstein, D. Lane, and A.J. Levine Surfing the p53 network Nature 408 2000 307 310
94. K.H. Vousden, and C. Prives Blinded by the light: the growing complexity of p53 Cell 137 2009 413 431
95. M. Wade, Y.V. Wang, and G.M. Wahl The p53 orchestra: Mdm2 and Mdmx set the tone Trends in Cell Biology 20 2010 299 309
96. C. Wanka, D.P. Brucker, O. Bahr, M. Ronellenfitsch, M. Weller, J.P. Steinbach, and J. Rieger Synthesis of cytochrome c oxidase 2: a p53-dependent metabolic regulator that promotes respiratory function and protects glioma and colon cancer cells from hypoxia-induced cell death Oncogene 31 2012 3764 3776
97. O. Warburg On the origin of cancer cells Science 123 1956 309 314
98. A. Willis, E.J. Jung, T. Wakefield, and X. Chen Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes Oncogene 23 2004 2330 2338
99. W.S. Wu, S. Heinrichs, D. Xu, S.P. Garrison, G.P. Zambetti, J.M. Adams, and A.T. Look Slug antagonizes p53-mediated apoptosis of hematopoietic progenitors by repressing puma Cell 123 2005 641 653
100. W. Xue, L. Zender, C. Miething, R.A. Dickins, E. Hernando, V. Krizhanovsky, C. Cordon-Cardo, and S.W. Lowe Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas Nature 445 2007 656 660
101. A. Yang, M. Kaghad, Y. Wang, E. Gillett, M.D. Fleming, V. Dotsch, N.C. Andrews, D. Caput, and F. McKeon p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities Molecular Cell 2 1998 305 316
102. A. Yang, R. Schweitzer, D. Sun, M. Kaghad, N. Walker, R.T. Bronson, C. Tabin, A. Sharpe, D. Caput, and C. Crum p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development Nature 398 1999 714 718
103. A. Yang, N. Walker, R. Bronson, M. Kaghad, M. Oosterwegel, J. Bonnin, C. Vagner, H. Bonnet, P. Dikkes, and A. Sharpe p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours Nature 404 2000 99 103
104. E. Yonish-Rouach, D. Resnitzky, J. Lotem, L. Sachs, A. Kimchi, and M. Oren Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6 Nature 352 1991 345 347
105. S. Zhou, S. Kachhap, and K.K. Singh Mitochondrial impairment in p53-deficient human cancer cells Mutagenesis 18 2003 287 292